All News
Filter News
Found 809,097 articles
-
Steven Damon Appointed Chief Executive Officer of Micron Biomedical, A Novel Vaccine and Therapeutic Technology Company
6/1/2020
Micron Biomedical, Inc., an Atlanta based biopharmaceutical company, has appointed industry veteran, Steven Damon , as the company CEO. Mr. Damon will lead Micron on a path to rapid development and commercialization of Micron's proprietary dissolvable, microneedle-based technology, a novel technology designed for simple, safe and effective
-
Neoleukin Therapeutics Announces Appointment of Erin Lavelle to Board of Directors
6/1/2020
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Erin Lavelle to the company’s Board of Directors.
-
Mitsubishi Tanabe Pharma Canada Announces That Company's Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Alberta
6/1/2020
Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), today announced that RADICAVA ® (edaravone) is now listed on the Alberta Drug Benefit List formulary (special authorization). RADICAVA is an intravenous infusion treatment for amyotrophic lateral sclerosis (ALS), a rapidly progressive, neur
-
San Diego Top Doctor Collaborates with Therapeutic Solutions International to Report QuadraMune™ Immune Boosting Data in Clinical Trial
6/1/2020
Scientifically Formulated Nutraceutical Product Appears to Stimulate Natural Killer Cell Arm of Immune System Responsible for Suppression of Cancer and Viruses
-
Mesa Labs Reports Fourth Quarter and Full Fiscal Year Results
6/1/2020
Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced results for the fourth quarter (“4Q20”) and full year ended March 31, 2020 (“FY20”).
-
Cancer Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Strategic Business Updates
6/1/2020
Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced financial and operating results for the fourth quarter and full year ended December 31, 2019.
-
Ocugen to Discontinue Phase 3 oGVHD TrialBreakthrough Modifier Gene Therapy platform continues to advance towards clinic
6/1/2020
Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat the whole eye, today announced the decision to discontinue the Phase 3 trial of OCU300 for ocular Graft vs. Host Disease (oGVHD). The decision to stop the trial is based on results of a pre-planned interim sample size analysis conducted by an independent Data Monitoring Committee, which indicated the trial
-
Henlius and Accord Receive Positive CHMP Opinion for Oncology Biosimilar, HLX02 (Trastuzumab)
6/1/2020
Shanghai Henlius Biotech, Inc. (2696.HK) and Accord Healthcare Limited (Accord) jointly announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation for biosimilar HLX02
-
SIGA Technologies Announces First International Delivery of Oral TPOXX®
6/1/2020
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced its first international delivery of TPOXX® (tecovirimat), with 2,500 courses delivered to the Canadian Department of National Defence (CDND). On April 3, 2020, the Company previously announced that the CDND is expected to purchase u
-
Theranica Kicks Off Migraine Awareness Month Rebate Program for Nerivio®, Its FDA-Authorized Migraine Treatment Wearable
6/1/2020
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced its Migraine Awareness Month $50 rebate for new Nerivio® prescriptions dispensed during June 2020.
-
CytRx Corporation Highlights Orphazyme's Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C
6/1/2020
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphayzme A/S announced they have initiated the submission of t
-
Change Healthcare Acquires PDX
6/1/2020
Today, Change Healthcare (Nasdaq: CHNG) announced the acquisition of PDX, a leader in providing patient centric and innovative technologies for pharmacies and health systems.
-
Cerner Names New Chief Technology OfficerJerome Labat Brings World-Class Expertise to Health Care Technology Leader
6/1/2020
Cerner Corporation (Nasdaq: CERN), a global health care technology company, announced today that Jerome Labat has joined the company as Chief Technology Officer (CTO). With more than 30 years’ experience in technology and product development leadership at other global Fortune 500 companies, including Hewlett Packard Enterprise Co. (HPE) and Oracle, Labat brings extensive experience in cloud automation, product portfolio strategy, Software
-
Mateon Provides Update on OT-101
6/1/2020
Mateon Therapeutics Inc. (OTCQB:MATN) report several peer-reviewed publications derived from its R&D effort against COVID-19. Fatih M. Uckun, Vuong Trieu. Targeting Transforming Growth Factor-beta for Treatment of COVID-19-associated Kawasaki Disease in Children. Clin Res Pediatr 2020; 3(1): 1-3 Fatih M. Uckun, Larn Hwang, Vuong Trieu. Selectively targeting TGF-β with Trabedersen/OT-101 in treatment of evolving and mild ARDS in
-
AbCellera’s Rapid Pandemic Response Platform Contributes to the World’s First COVID-19 Clinical Trial for a Potential Monoclonal Antibody Treatment
6/1/2020
AbCellera today announced that LY-CoV555, the lead antibody from the collaboration between AbCellera and Eli Lilly and Company (Lilly), has entered into human testing for the potential treatment of COVID-19.
-
Natera Launches Quantification Technique to Enhance Prospera™ Test Precision; Initiates PEDAL Study for New Insights
6/1/2020
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, is pleased to announce the launch of a novel technique to enhance results from the Prospera donor-derived cell-free DNA (dd-cfDNA) transplant reject
-
AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
6/1/2020
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for RINVOQ™ (upadacitinib; 15 mg, once daily), a selective and reversible JAK inhibitor
-
Kewaunee Scientific Announces the Appointment of a New Vice President of Manufacturing Operations
6/1/2020
Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced that Douglas J. Batdorff has joined the Company as Vice President of Manufacturing Operations. Mr. Batdorff will have responsibility for all of Kewaunee's domestic manufacturing operations.
-
3NT Medical Announces FDA Clearance for Colibri™ Endoscopy System
6/1/2020
3NT Medical, a privately-held corporation dedicated to developing single-use specialized endoscopes for the diagnosis and treatment of ear, nose and throat (ENT) disorders, announced today the FDA 510(k) clearance for the C
-
Primo Nutraceuticals Announces No Material Change
6/1/2020
PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Primo” or the “Company”) is issuing this press release in response to a request by the Investment Industry Regulatory Organization of Canada to comment on recent trading activity of its common shares.